Efalizumab (Raptiva), an investigational therapy for moderate-to-severe psoriasis, achieved its primary efficacy endpoint in a randomized phase III study.
Derm In The News: September 22-28
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Deuruxolitinib Shows Efficacy in Hair Regrowth, Patient Satisfaction, and Psychosocial Wellbeing in Severe Alopecia Areata
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Melinda Gooderham, MSc, MD, FRCPC: Insights Into Lebrikizumab’s Sustained 3-Year Efficacy
Positive Results Reported in Roflumilast 0.15% for AD Across Diverse Populations